• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2受体结合结构域与ACE2细胞受体相互作用的肽类抑制剂。

Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor.

作者信息

Bibilashvili R Sh, Sidorova M V, Dudkina U S, Palkeeva M E, Molokoedov A S, Kozlovskaya L I, Egorov A M, Ishmukhametov A A, Parfyonova E V

机构信息

National Medical Research Center for Cardiology, 3rd Cherepkovskaya 15А, 121552 Moscow, Russia.

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological products of the Russian Academy of Sciences, 108819 Moscow, Russia.

出版信息

Biochem Mosc Suppl B Biomed Chem. 2021;15(4):274-280. doi: 10.1134/S199075082104003X. Epub 2021 Nov 2.

DOI:10.1134/S199075082104003X
PMID:34745440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8562373/
Abstract

Computer simulation has been used to identify peptides that mimic the natural target of the SARS-CoV-2 coronavirus spike (S) protein, the angiotensin-converting enzyme type 2 (ACE2) cell receptor. Based on the structure of the complex of the protein S receptor-binding domain (RBD) and ACE2, the design of chimeric molecules consisting of two 22-23-mer peptides linked to each other by disulfide bonds was carried out. The chimeric molecule X1 was a disulfide dimer, in which terminal cysteine residues in the precursor molecules h1 and h2 were connected by the S-S bond. In the chimeric molecule X2, the disulfide bond was located in the middle of each precursor peptide molecule. The precursors h1 and h2 mimic amino acid sequences of α1- and α2-helices of the ACE2 extracellular peptidase domain, respectively, keeping intact most of the amino acid residues involved in the interaction with RBD. The aim of the work was to evaluate the binding efficiency of chimeric molecules and their constituent peptides with RBD (particularly in dependence of the middle and terminal methods of fixing the initial peptides h1 and h2). The proposed polypeptides and chimeric molecules were synthesized by chemical methods, purified to 95-97% purity, and characterized by HPLC and MALDI-TOF mass spectrometry. Binding of these peptides to the SARS-CoV-2 RBD was evaluated by microthermophoresis with recombinant domains corresponding in sequence to the original Chinese (GenBank ID NC_045512.2) and the British (B. 1.1.7, GISAID EPI_ISL_683466) variants. The original RBD of the Chinese variant bound to three synthesized peptides: linear h2 and both chimeric variants. Chimeric peptides were also bound to the RBD of the British variant. The antiviral activity of the proposed peptides was evaluated in Vero cell line.

摘要

计算机模拟已被用于识别模拟严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突(S)蛋白天然靶标的肽,即2型血管紧张素转换酶(ACE2)细胞受体。基于S蛋白受体结合结构域(RBD)与ACE2复合物的结构,开展了由通过二硫键相互连接的两个22 - 23肽组成的嵌合分子的设计。嵌合分子X1是一种二硫键二聚体,其中前体分子h1和h2中的末端半胱氨酸残基通过S - S键连接。在嵌合分子X2中,二硫键位于每个前体肽分子的中间。前体h1和h2分别模拟ACE2细胞外肽酶结构域α1和α2螺旋的氨基酸序列,与RBD相互作用的大多数氨基酸残基保持完整。这项工作的目的是评估嵌合分子及其组成肽与RBD的结合效率(特别是取决于固定初始肽h1和h2的中间和末端方法)。所提出的多肽和嵌合分子通过化学方法合成,纯化至纯度为95 - 97%,并通过高效液相色谱(HPLC)和基质辅助激光解吸电离飞行时间质谱(MALDI - TOF)进行表征。通过微量热泳技术,使用与原始中国株(GenBank ID NC_045512.2)和英国株(B. 1.1.7,GISAID EPI_ISL_683466)变体序列对应的重组结构域,评估了这些肽与SARS-CoV-2 RBD的结合。中国变体的原始RBD与三种合成肽结合:线性h2和两种嵌合变体。嵌合肽也与英国变体的RBD结合。在所提出的肽在Vero细胞系中评估了其抗病毒活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56d2/8562373/26a4d900f182/11828_2021_5120_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56d2/8562373/37a94fd92915/11828_2021_5120_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56d2/8562373/26a4d900f182/11828_2021_5120_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56d2/8562373/37a94fd92915/11828_2021_5120_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56d2/8562373/26a4d900f182/11828_2021_5120_Fig2_HTML.jpg

相似文献

1
Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor.严重急性呼吸综合征冠状病毒2受体结合结构域与ACE2细胞受体相互作用的肽类抑制剂。
Biochem Mosc Suppl B Biomed Chem. 2021;15(4):274-280. doi: 10.1134/S199075082104003X. Epub 2021 Nov 2.
2
[Peptide inhibitors of the interaction of the SARS-CoV-2 receptor-binding domain with the ACE2 cell receptor].[严重急性呼吸综合征冠状病毒2受体结合结构域与血管紧张素转换酶2细胞受体相互作用的肽抑制剂]
Biomed Khim. 2021 May;67(3):244-250. doi: 10.18097/PBMC20216703244.
3
Properties and Activity of Peptide Derivatives of ACE2 Cellular Receptor and Their Interaction with SARS-CoV-2 S Protein Receptor-Binding Domain.ACE2 细胞受体的肽衍生物的特性和活性及其与 SARS-CoV-2 S 蛋白受体结合域的相互作用。
Dokl Biochem Biophys. 2022 Dec;507(1):237-241. doi: 10.1134/S1607672922060126. Epub 2022 Dec 29.
4
Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor.基于 SARS-CoV-2 刺突蛋白与人类 ACE2 受体结合表位的结构特征,设计结合亲和力优于 ACE2 受体的肽类抑制剂。
Sci Rep. 2021 Aug 2;11(1):15650. doi: 10.1038/s41598-021-94873-3.
5
Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.用于阻断新冠病毒刺突蛋白受体结合域的潜在嵌合肽。
F1000Res. 2020 Jun 9;9:576. doi: 10.12688/f1000research.24074.1. eCollection 2020.
6
Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.SARS-CoV-2 刺突 RBD 与人 ACE2 蛋白-蛋白相互作用的生物力学特性分析。
Biophys J. 2021 Mar 16;120(6):1011-1019. doi: 10.1016/j.bpj.2021.02.007. Epub 2021 Feb 17.
7
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.针对关注的 SARS-CoV-2 变体的中和抗体的表位分类和 RBD 结合特性。
Front Immunol. 2021 Jun 4;12:691715. doi: 10.3389/fimmu.2021.691715. eCollection 2021.
8
Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的抑制剂筛选及其阻断病毒进入机制的能力:一项病毒信息学研究。
Saudi J Biol Sci. 2021 Jun;28(6):3262-3269. doi: 10.1016/j.sjbs.2021.02.066. Epub 2021 Feb 26.
9
Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection .基于人血管紧张素转化酶 2(ACE2)的订书肽强烈抑制 SARS-CoV-2 感染。
mBio. 2020 Dec 11;11(6):e02451-20. doi: 10.1128/mBio.02451-20.
10
Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction.基于结构的虚拟筛选及新型冠状病毒刺突蛋白受体结合域与血管紧张素转换酶2相互作用潜在抑制剂的鉴定
Front Chem. 2021 Sep 27;9:740702. doi: 10.3389/fchem.2021.740702. eCollection 2021.

引用本文的文献

1
A Piecewise Design Approach to Engineering a Miniature ACE2 Mimic to Bind SARS-CoV-2.分段设计方法工程化 ACE2 类似物以结合 SARS-CoV-2
ACS Appl Bio Mater. 2024 May 20;7(5):3238-3246. doi: 10.1021/acsabm.4c00222. Epub 2024 May 3.
2
Peptide foldamer-based inhibitors of the SARS-CoV-2 S protein-human ACE2 interaction.基于肽折叠物的 SARS-CoV-2 刺突蛋白-人 ACE2 相互作用抑制剂。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2244693. doi: 10.1080/14756366.2023.2244693.
3
Advances in developing ACE2 derivatives against SARS-CoV-2.

本文引用的文献

1
Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.具有多种抗 RNA 和 DNA 病毒活性的吩嗪核苷衍生物。
Eur J Med Chem. 2021 Aug 5;220:113467. doi: 10.1016/j.ejmech.2021.113467. Epub 2021 Apr 15.
2
Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白与血管紧张素转换酶2(ACE2)结合的不同状态的结构基础。
Cell Res. 2021 Jun;31(6):717-719. doi: 10.1038/s41422-021-00490-0. Epub 2021 Mar 18.
3
Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization.
开发针对 SARS-CoV-2 的 ACE2 衍生物的进展。
Lancet Microbe. 2023 May;4(5):e369-e378. doi: 10.1016/S2666-5247(23)00011-3. Epub 2023 Mar 16.
4
Will Peptides Help to Stop COVID-19?多肽能否有助于阻止 COVID-19?
Biochemistry (Mosc). 2022 Jul;87(7):590-604. doi: 10.1134/S0006297922070021.
旨在靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的钉合血管紧张素转换酶2(ACE2)拟肽不能阻止病毒内化。
Pept Sci (Hoboken). 2021 Jul;113(4):e24217. doi: 10.1002/pep2.24217. Epub 2021 Jan 8.
4
Isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during the COVID-19 outbreak.在 COVID-19 疫情期间收集的俄罗斯 SARS-CoV-2 变异株的分离和系统发育分析。
Int J Infect Dis. 2020 Oct;99:40-46. doi: 10.1016/j.ijid.2020.07.024. Epub 2020 Jul 25.
5
design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2.设计蛋白质肽以阻断严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白与人血管紧张素转换酶2(ACE2)的结合。
Aging (Albany NY). 2020 Jun 16;12(12):11263-11276. doi: 10.18632/aging.103416.
6
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.使用临床级别的可溶性人血管紧张素转化酶 2 抑制工程化人类组织中的 SARS-CoV-2 感染。
Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.
7
Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2.基于 ACE2 的 SARS-CoV-2 肽抑制剂的计算设计。
ACS Nano. 2020 Apr 28;14(4):5143-5147. doi: 10.1021/acsnano.0c02857. Epub 2020 Apr 16.
8
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.一种口服生物利用度的广谱抗病毒药物可抑制人呼吸道上皮细胞培养中的 SARS-CoV-2 病毒和小鼠中的多种冠状病毒。
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
9
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.严重急性呼吸系统综合征冠状病毒 2 刺突糖蛋白的结构、功能和抗原性。
Cell. 2020 Apr 16;181(2):281-292.e6. doi: 10.1016/j.cell.2020.02.058. Epub 2020 Mar 9.
10
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.2019 年新型冠状病毒刺突蛋白在预融合构象的冷冻电镜结构
Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19.